Clinical trials: Carfilzomib
Hodgkin Disease, Lymphoma, Non-hodgkin
Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma
This is an open label, phase I/II, dose-escalation study in the initial phase I followed by a phase II. The primary objective of the phase I is to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of the…
- Trial name
- NCT02867618
- Testing
- Carfilzomib, TGR-1202
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Columbia University
Multiple Myeloma, Smoldering Multiple Myeloma
A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
The purpose of this study is to determine the efficacy of treating patients with intermediate risk smoldering multiple myeloma (SMM) with combinational therapy with dexamethasone and lenalidomide (Rd) and patients with high risk…
- Trial name
- iStopMM (NCT03815279)
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- Iceland
- Volunteers
- 80 people
- Sponsor
- Landspitali University Hospital
Multiple Myeloma
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
Based on the pre-clinical data the investigators hypothesize that G-CSF treatment in patients with multiple myeloma will generate a 'hostile' bone marrow microenvironment for myeloma cells, depriving them of key support signals…
- Trial name
- NCT01537861
- Testing
- Filgrastim, Bortezomib, Carfilzomib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
This study is for adults with multiple myeloma (a type of blood cancer) that has come back after being treated earlier or isn't responding to the current treatment.
- Trial name
- NCT07227311
- Testing
- Belantamab mafodotin, Dexamethasone, Pomalidomide
- Where
- 59 sites in United States, France and 6 more
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd)…
- Trial name
- Iber-KDd (NCT05896228)
- Testing
- Iberdomide, Carfilzomib, Daratumumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Benjamin T Diamond, MD
Multiple Myeloma
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma.
- Trial name
- NCT05137054
- Testing
- Linvoseltamab, Daratumumab, Carfilzomib
- Where
- 42 sites in United States, France and 3 more
- Volunteers
- 317 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma
The purpose of this study is to find out what effects, good and/or bad, the combination of panobinostat and carfilzomib have on the patient's cancer.
- Trial name
- NCT01549431
- Testing
- Panobinostat, Carfilzomib, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Emory University
Multiple Myeloma in Relapse
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
Selinexor (KPT-330, Xpovio) is a first in class selective inhibitor of nuclear export which has been approved for use in relapsed and refractory multiple myeloma (RRMM).
- Trial name
- NCT04925193
- Testing
- Selinexor, Pomalidomide, Daratumumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Colorado, Denver
Multiple Myeloma
A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma
This study will evaluate GMI-1271, a specific E-selectin antagonist, in multiple myeloma as adjunct to standard of care chemotherapy used to treat this disease.
- Trial name
- NCT02811822
- Testing
- GMI-1271
- Where
- 8 sites in Denmark, Germany and 2 more
- Volunteers
- 10 people
- Sponsor
- GlycoMimetics Incorporated
Metastatic Castration-resistant Prostate Cancer
Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment
This study will test how effective the drug, Carfilzomib, reduces progression of prostate cancer in patients who have previously received chemotherapy and androgen inhibitors.
- Trial name
- NCT02047253
- Testing
- Carfilzomib, Dexamethasone, Acyclovir
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Alabama at Birmingham
Multiple Myeloma
Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma
Multiple myeloma (MM) is a neoplastic expansion of bone marrow plasma cells. Despite advances in treatment in recent years, MM is still a fatal disease.
- Trial name
- MYELOMA-HCQ (NCT04163107)
- Testing
- Hydroxychloroquine, Carfilzomib Injection, Dexamethasone
- Where
- 2 sites in Norway
- Volunteers
- 19 people
- Sponsor
- Norwegian University of Science and Technology
Multiple Myeloma
Cost-Utility Analysis of Home-based Versus Hospital-based Chemotherapy in Multiple Myeloma: Case of Carfilzomib
Carfilzomib is administered in treatment of Multiple Myeloma intravenously on two consecutive days, each week for three weeks (days 1, 2, 8, 9, 15, and 16), followed by a 12-day rest period (days 17 to 28).
- Trial name
- ADHOMY2 (NCT05184595)
- Testing
- Carfilzomib delivered in OH only, Carfilzomib delivered in OH and HaH combined
- Volunteers
- 52 people
- Sponsor
- Central Hospital, Nancy, France
Plasma Cell Myeloma
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well they work compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma.
- Trial name
- NCT01863550
- Testing
- Bortezomib, Carfilzomib, Dexamethasone
- Where
- 920 sites in United States, Puerto Rico
- Volunteers
- 1,087 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
This phase Ib/II trial compares the effect of teclistamab and pomalidomide to standard treatment with carfilzomib, pomalidomide and dexamethasone in treating patients with multiple myeloma that has come back after a period of…
- Trial name
- NCT07463807
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- National Cancer Institute (NCI)
T-cell Lymphomas, Relapsed or Refractory
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
This is an open label phase Ib/IIa study of patients with relapsed/refractory B- and T-cell lymphomas who are treated with carfilzomib, lenalidomide and romidepsin.
- Trial name
- NCT02341014
- Testing
- Carfilzomib, Romidepsin, Lenalidomide
- Where
- 6 sites in United States
- Volunteers
- 27 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and…
- Trial name
- CarMob (NCT03909412)
- Testing
- Carfilzomib, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Hackensack Meridian Health
Multiple Myeloma
Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma
This is a multicenter, open label, phase II randomized controlled study that will evaluate the efficacy of carfilzomib and dexamethasone in combination with cyclophosphamide in R/R MM patients.
- Trial name
- NCT03336073
- Testing
- Carfilzomib, Dexamethasone, cyclophosphamide
- Where
- 24 sites in Spain
- Volunteers
- 199 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma
Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma
IFM 2012-03 protocol is a Phase 2 multicenter nonrandomized open in elderly patients with multiple myeloma at diagnosis. Study primary objectives are in the first step to determine Maximum tolerated dose (MTD) of Carfilzomib…
- Trial name
- IFM2012-03 (NCT02302495)
- Testing
- Carfilzomib
- Where
- 33 sites in France
- Volunteers
- 32 people
- Sponsor
- University Hospital, Lille
Multiple Myeloma
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
- Trial name
- NCT03989414
- Testing
- CC-92480, Bortezomib, Dexamethasone
- Where
- 49 sites in United States, Canada and 7 more
- Volunteers
- 424 people
- Sponsor
- Celgene
Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma
Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
This phase I trial studies the side effects and best dose of filanesib when given together with carfilzomib in treating patients with multiple myeloma or plasma cell leukemia that has returned or does not respond to treatment.
- Conditions
- Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT01372540
- Testing
- Carfilzomib, Filanesib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- M.D. Anderson Cancer Center